[Pathology of the endometrium in breast cancer patients treated with tamoxifen (nolvadex)].
The objectives of this study were to: 1) characterize histologically endometrial biopsy findings for genital bleeding in breast cancer patients receiving Tamoxifen; 2) analyze histologically endometrial carcinoma in the same patients. We analyzed biopsy specimens divided into three groups: 1) 112 biopsies (curettages and hysterectomy specimens) from 88 breast cancer patients receiving Tamoxifen (Nolvadex): T+; 2) 27 biopsies (curettages and hysterectomy specimens) from 22 breast cancer patients not receiving Tamoxifen but biopsied for genital bleeding: T-; 3) 139 curettages control samples received for analysis in the period January-March 2000 from women with peri- and postmenopausal genital bleeding: K. The analysis was performed on archival H&E sections. The most frequent finding in breast cancer patients receiving Tamoxifen was endometrial polyp. Compared with the other two groups (T- and K) the frequency of this finding was statistically significant. No difference was found in the prevalence of endometrial cancer between the three groups. The analyzed endometrial carcinomas in Tamoxifen-treated breast cancer patients show signs, characteristic of Bochman type I: predominantly endometrioid, of low grade and FIGO stage, with good prognosis.
Ivanova
V
V
Karaivanov
M
M
Marinov
E
E
Gorchev
G
G
Velkova
A
A
Khristova
P
P
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy; D016889:Endometrial Neoplasms / Q000209:etiology* / Q000473:pathology; D004717:Endometrium / Q000473:pathology*; D005260:Female; D006801:Humans; D011127:Polyps / Q000209:etiology* / Q000473:pathology; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen